Long‐term outcome after a treosulfan‐based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cancer

• Publication date

  2017-07-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.30646PMID 28329410
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies

  2016influential reference
• Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee.

  2016cited by this paper
• Survival Impact of Early Post-Transplant Toxicities in Pediatric and Adolescent Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Malignant and Nonmalignant Diseases: Recognizing Risks and Optimizing Outcomes.

  2016influential reference
• RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT

  2016cited by this paper
• Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT

  2016cited by this paper
• Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment.

  2016influential reference
• Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.

  2015cited by this paper
• Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases

  2015cited by this paper
• Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia

  2015influential reference
• Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT

  2015cited by this paper
• Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis.

  2015cited by this paper
• Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL)

  2015influential reference
• Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.

  2014influential reference
• Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma.

  2014cited by this paper
• Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial.

  2014cited by this paper
• Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics.

  2014influential reference
• Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan

  2013influential reference
• Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.

  2013influential reference
• Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.

  2013cited by this paper
• Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and

  2013cited by this paper
• Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions.

  2013influential reference
• Time to explore preventive and novel therapies for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.

  2012cited by this paper
• Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning

  2012cited by this paper
• Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity

  2012cited by this paper
• Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike

  2012cited by this paper
• The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade.

  2011cited by this paper
• Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party

  2011influential reference
• Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns.

  2011influential reference
• Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning

  2011influential reference
• Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning.

  2010cited by this paper
• Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.

  2009influential reference
• Solid cancers after allogeneic hematopoietic cell transplantation.

  2009influential reference
• Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT

  2008influential reference
• Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients

  2008influential reference
• Fludarabine and treosulfan: A novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes

  2007cited by this paper
• Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)

  2006cited by this paper
• Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation.

  2005cited by this paper
• Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.

  2004influential reference
• Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1.

  2004influential reference
• Towards a myeloablative regimen with clinical potential: I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers

  2003influential reference
• Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients

  2003influential reference
• Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL).

  2003influential reference
• Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies.

  2000influential reference

• Intensification of Treosulfan-Fludarabine Conditioning With Thiotepa Exhibited Effectiveness and Tolerability in Older or Comorbid Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant With Active Myeloid Neoplasm: A Real-world Study

  2026cites this paper
• Impact of busulfan- versus treosulfan-based conditioning on the incidence of sinusoidal obstruction syndrome/veno-occlusive disease after allogeneic hematopoietic cell transplantation: a dual-center real-world study

  2025cites this paper
• Treosulfan-Based Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Other Myeloid Malignancies

  2025cites this paper
• Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients

  2024cites this paper
• Outpatient management of patients conditioned with Fludarabine and Treosulfan prior to allogeneic hematopoietic cell transplantation.

  2024cites this paper
• Sequential conditioning with FLAMSA does not improve outcomes of allogeneic stem cell transplantation in CMML patients.

  2024cites this paper
• Treosulfan-Versus Melphalan-Based Reduced Intensity Conditioning in HLA-Haploidentical Transplantation for Patients ≥ 50 Years with Advanced MDS/AML

  2024cites this paper
• Determinants of Interpatient Variability in Treosulfan Pharmacokinetics in AML Patients Undergoing Autologous Stem Cell Transplantation

  2024cites this paper
• Treosulfan is a safe and effective alternative to busulfan for conditioning in adult allogeneic HSCT patients: Data from a single center

  2024cites this paper
• Novel conditioning and prophylaxis regimens for relapse prevention.

  2024cites this paper
• Treosulfan- versus busulfan-based conditioning in allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: a single-center retrospective propensity score-matched cohort study.

  2024cites this paper
• Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison

  2024cites this paper
• Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis

  2023cites this paper
• Is Treosulfan-Based Conditioning Attractive as a Reduced-Intensity Conditioning Regimen in Korea?

  2023cites this paper
• Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT

  2023cites this paper
• Incidence of sinusoidal obstruction syndrome/veno-occlusive disease and treatment with defibrotide in allogeneic transplant: A multicentre Australasian registry study.

  2023cites this paper
• Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT

  2023influential citation
• Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party

  2022cites this paper
• Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis

  2022cites this paper
• Comparison of Melphalan Combined with Treosulfan or Busulfan as High-Dose Chemotherapy before Autologous Stem Cell Transplantation in AML

  2022influential citation
• Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia

  2021cites this paper
• Treatment of acute myeloid leukemia in children: A practical perspective

  2021cites this paper
• Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced‐intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT

  2021cites this paper
• Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial

  2021cites this paper
• Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms

  2021cites this paper
• Conditioning Regimens for Frail Patients with Acute Leukemia Undergoing Allogeneic Stem Cell Transplant: How to Strike Gently

  2021influential citation
• Treosulfan – fl udarabine – thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies

  2020cites this paper
• Long-Term Outcomes of Treosulfan- vs. Busulfan-Based Conditioning Regimen for Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia Before Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis

  2020cites this paper
• Late Effects in Children and Adolescents with Ewing Sarcoma

  2020cites this paper
• Early clinical course after hematopoietic stem cell transplantation in children with juvenile metachromatic leukodystrophy

  2020cites this paper
• Reduced-intensity versus myeloablative conditioning in cord blood transplantation for AML (40-60 years) across highly mismatched HLA barriers - On behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT.

  2020cites this paper
• Fear of disease progression and relevant correlates in acute leukemia patients prior to allogeneic hematopoietic stem cell transplantation

  2020cites this paper
• Treosulfan–fludarabine–thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies

  2020cites this paper
• Clofarabine and Treosulfan as conditioning for matched related and unrelated HSCT: results from the phase II trial "Clo3o".

  2020cites this paper
• Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

  2019cites this paper
• Pre-formulation investigations for establishing a protocol for treosulfan handling and activation

  2019cites this paper
• In Vivo Red Blood Cells/Plasma Partition Coefficient of Treosulfan and Its Active Monoepoxide in Rats

  2018cites this paper
• Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy

  2018cites this paper
• Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis

  2018cites this paper
• Conditioning

  2018cites this paper
• Treosulfan Pharmacokinetics and its Variability in Pediatric and Adult Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation: Current State of the Art, In-Depth Analysis, and Perspectives

  2018cites this paper
• Clinical bioanalysis of treosulfan and its epoxides: The importance of collected blood processing for valid pharmacokinetic results

  2018cites this paper
• Disposition of treosulfan and its active monoepoxide in a bone marrow, liver, lungs, brain, and muscle: Studies in a rat model with clinical relevance

  2017influential citation
• Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia.

  2017cites this paper
• Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation.

  2017cites this paper